Abstract
Introduction Localized Provoked Vulvodynia (LPV) is a quite common form of sexual pain among young women. Primary LPV (e.g. pain from the first attempted intercourse) and secondary LPV (pain-free time period before the initiation of symptoms) have been suggested to develop via different pathomechanisms. As inflammation is one possible trigger in LPV, changes in vaginal and/or vulvar microbiome may be an initiator of the inflammatory process leading to peripheral neurosensitization and predisposing women to LPV.
Aim Aim of this pilot study was to find out, whether there are differences in vestibular microbiome between LPV patients and controls.
Materials and Methods Thirty women with LPV (8 with primary and 22 with secondary LPV) and 21 controls were prospectively recruited to the study from Kanta-Häme Central Hospital and Tampere University Hospital (TAUH). Paired vestibular samples were collected in clinical outpatient setting and analyzed with 16s rRNA sequencing.
Results LPV patients had lower BMI, were younger and more often nulliparous than controls. Patients with secondary vulvodynia had reduced (p = 0.06) bacterial species diversity (alpha diversity) and more clustered (p= 0.05) vaginal microbiome community (beta diversity) compared to healthy controls. Differential abundance analysis identified 31 bacterial taxa that contributed to the difference in bacterial composition between secondary cases and controls (p < 0.05). Bacteria taxa that were increased among patients were Gardneralla vaginalis (p<0.0001), Peptoniphilus spp (p<0.0001), Prevotella amnii (p<0.0001) and Streptococcus spp (p=0.0001). Several bacterial species were more abundant among healthy controls reflecting reduced bacterial diversity among patients.
Conclusion In patients with secondary LPV changes in vulvar microbiome may contribute to pathogenesis of LPV and ultimately lead to targeted therapeutic options. These preliminary findings need to be confirmed in a larger study.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Kanta-Häme Cultural Foundation
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflicts of Interest and Source of Funding: The study has been financially supported by the Academy of Finland: grants (322098 and 286284 for T.L), Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospitals (grant X51001 for T.L, P.K); Finnish Foundation for Cardiovascular Research (T:L, P.K); Tampere Tuberculosis Foundation (T.L and P.K); Emil Aaltonen Foundation (T.L); Yrjö Jahnsson Foundation; Signe and Ane Gyllenberg Foundation; Diabetes Research Foundation of Finnish Diabetes Association; EU Horizon 2020 (grant 755320 for TAXINOMISIS); Kanta-Häme Cultural Foundation (A.A) and Tampere University Hospital Supporting Foundation.
Data Availability
The data is available upon request from the corresponding author
